文献速递血液净化与透析

Difelikefalin 改善血液透析患者瘙痒相关睡眠障碍

Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

该事后分析基于 3 期 difelikefalin 研究(Study 3105 及 KALM-1/2 汇总),评估血液透析合并中重度 CKD 相关瘙痒患者瘙痒减轻与睡眠质量改善的关系。结果显示,WI-NRS 改善≥3 分者睡眠质量改善幅度大于<3 分者;瘙痒减轻与睡眠改善相关。

要点

  • 血液透析伴中重度 CKD 相关瘙痒患者中,difelikefalin 减轻瘙痒与睡眠质量改善相关。
  • Study 3105 中 WI-NRS 改善≥3 分者 SQ-NRS 平均降低 5.2,<3 分者降低 1.5。
  • KALM-1/2 汇总中 WI-NRS 改善≥3 分者 5-D SDQ 平均降低 1.8,<3 分者降低 0.8。

核心结论

  • 在接受血液透析的中重度 CKD 相关瘙痒患者中,静脉 difelikefalin 减轻瘙痒与睡眠质量改善相关。
  • 瘙痒减轻可能通过改善睡眠质量帮助解决 CKD 相关瘙痒的重要临床负担。

研究设计与样本

  • 3 期 difelikefalin 研究(Study 3105 及 KALM-1 与 KALM-2 汇总数据集)的事后分析。
  • Study 3105 中 difelikefalin 组 N=222;KALM-1 和 KALM-2 汇总中 difelikefalin 组 N=426、安慰剂组 N=425。
  • difelikefalin 剂量为 0.5 µg/kg 静脉给药、每周三次,疗程 12 周。
  • 瘙痒强度用 WI-NRS 评估;睡眠质量用 5-D 瘙痒量表睡眠障碍问题(5-D SDQ)评估,Study 3105 另用睡眠质量数字评定量表(SQ-NRS)评估。

主要发现

  • Study 3105 中,WI-NRS 改善≥3 分者 SQ-NRS 平均降低 5.2(95%CI -5.6, -4.8),改善<3 分者降低 1.5(95%CI -2.0, -1.0)。
  • KALM-1 和 KALM-2 汇总中,WI-NRS 改善≥3 分者 5-D SDQ 平均降低 1.8(95%CI -2.1, -1.6),改善<3 分者降低 0.8(95%CI -1.1, -0.4)。
  • Study 3105 中 SQ-NRS 与 WI-NRS 评分在基线及第 12 周均高度相关(Spearman 相关系数分别为 0.77 和 0.84)。
  • Study 3105 及 KALM-1 和 KALM-2 中亦观察到 5-D SDQ 与 WI-NRS 评分之间的相关性。

临床怎么用

  • 对于血液透析合并中重度 CKD 相关瘙痒的患者,difelikefalin 减轻瘙痒的同时可能改善睡眠质量。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Poor sleep quality is associated with higher mortality and lower quality of life in patients with chronic kidney disease-associated pruritus (CKD-aP). Difelikefalin reduces itch in patients with CKD-aP undergoing haemodialysis (HD). This post hoc analysis of the Phase 3 difelikefalin studies (Study 3105 and the pooled dataset from KALM-1 and KALM-2) evaluated whether itch reduction in individuals with CKD-aP improved sleep quality. METHODS: Itch intensity was assessed in patients undergoing HD who had moderate-to-severe CKD-aP treated with intravenous difelikefalin (0.5 µg/kg, three times weekly) (N = 222, Study 3105; N = 426, KALM-1 and -2) or placebo (N = 425, KALM-1 and -2) for 12 weeks, using the Worst Itch Intensity Numerical Rating Scale (WI-NRS). Sleep quality was assessed using the sleep disability question of the 5-D Itch Scale (5-D SDQ) in all studies and, in Study 3105, with the Sleep Quality Numeric Rating Scale (SQ-NRS). RESULTS: Greater improvements in sleep quality were observed in patients with ≥3-point versus <3-point WI-NRS improvement using SQ-NRS in Study 3105 [mean (95% confidence interval) -5.2 (-5.6, -4.8) vs -1.5 (-2.0, -1.0)] and 5-D SDQ in KALM-1 and -2 [-1.8 (-2.1, -1.6) vs -0.8 (-1.1, -0.4)]. SQ-NRS and WI-NRS scores were highly correlated at both baseline and Week 12 in Study 3105 (Spearman correlation coefficient: 0.77 and 0.84, respectively). Correlations were also observed between 5-D SDQ and WI-NRS scores in Study 3105 and KALM-1 and -2. CONCLUSIONS: In patients undergoing HD with moderate-to-severe CKD-aP, itch reduction with intravenous difelikefalin was associated with improved sleep quality. As disturbed sleep may contribute to mortality and morbidity in CKD-aP, difelikefalin may help to address a major clinical burden by improving sleep quality, secondary to itch relief. TRIAL REGISTRATION: KALM-1 (NCT03422653), KALM-2 (NCT03636269), Study 3105 (NCT03998163).

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Weiner DE, Schaufler T, McCafferty K, et al. Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis. Nephrol Dial Transplant. 2024. PMID: 37968132. doi:10.1093/ndt/gfad245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。